Table 5 Follow-up data
Variables | Extracorporeal (n = 19) | Intracorporeal (n = 19) | P |
|---|---|---|---|
Follow-up time (mean ± SD), months | 48.7 ± 30.58 | 26.4 ± 8.29 | 0.329 |
Post- eGFR (mean ± SD), mL/(min·1.73 m2) | 79.0 ± 19.95 | 86.2 ± 34.7 | 0.516 |
30-day complication rates, n (%) | 0.227 | ||
Minor (I–II) | 9 (47%) | 5 (32%) | 0.313 |
Major (III–V) | 1 (5%) | 1 (5%) | > 0.9 |
90-day complication rates, n (%) | 0.142 | ||
Minor (I–II) | 1 (5%) | 2 (11%) | > 0.9 |
Major (III–V) | 0 (0%) | 2 (11%) | 0.486 |
Metastasis, n (%) | 2 (11%) | 5 (26%) | 0.405 |
Overall survival, n (%) | 16 (84%) | 17 (89%) | > 0.9 |